NeurologyLive

Take a look at NeurologyLive's latest feature📖: a sneak peek into Cleveland Clinic's upcoming Neurological Institute, a $1.1 billion marvel set to open in early 2027. Featuring insights from Andre Machado, MD, PhD, and architect Upesh Dhaji, this piece explores the intricate details of this groundbreaking pavilion and how it aims to transform neurological care with cutting-edge, patient-centered design and innovation. Read more: https://hubs.li/Q03h0xJt0

Experts discuss how to optimize treatment for patients with CIDP focusing on both the current and emerging treatment options as well as how these impact patients’ quality of life. Watch the video Optimizing CIDP Care While Navigating New Approvals and Patient Preferences to learn more: https://hubs.li/Q03jJpPW0 #CIPD

The FDA has granted De Novo authorization to Epiminder's Minder, an implantable continuous electroencephalogram monitoring system (iCEM), marking it as the first device of its kind approved in the U.S. for patients with epilepsy. The device is expected to formally launch in the second half of 2025 through a phased rollout at leading epilepsy centers as part of the company’s strategy to demonstrate the system’s clinical utility. Read: https://hubs.li/Q03jJpQH0

A study published in JAMA Neurology revealed that the risk of developing Alzheimer disease was significantly lower in patients with type 2 diabetes on GLP-1RAs and SGLT2is rather than those on other glucose-lowering drugs. Overall, the study found no difference in the risk of AD and other related dementias between both GLP-1RAs and SGLT2is. Our coverage: https://hubs.li/Q03jJsrp0

Collaboration drives progress. At NeurologyLive, we’re proud to work with leading voices in Neurology—like Anne Marie Morse, DO, FAASM—who help us deliver content that matters to today’s healthcare professionals. Catch their latest insights: https://hubs.li/Q03jHZxD0 #NeurologyExperts #BrainHealth

Innovation in “On” time is here. Watch the on-demand broadcast to listen to Robert A. Hauser, MD, FAAN, Stuart Isaacson, MD, FAAN, and Neepa J. Patel, MD discuss a new treatment option for adult patients with Parkinson’s disease #PD. bit.ly/48SDjG5

💊 In a phase 1 study, intranasal zavegepant, a CGRP receptor antagonist approved for acute #migraine, showed no meaningful impact on the pharmacokinetics of a single-dose oral contraceptive in healthy adult women. Pfizer 🔗 Read more: https://hubs.li/Q03jjvHS0

NeurologyLive chatted with Ken Mariash, CEO of Sinaptica Therapeutics (a member of our Alzheimer's Moonshot Community), to get greater insights on the significance of the findings from the company's 52-week double-blind, sham-controlled trial showing how personalized repetitive transcranial magnetic stimulation may transform Alzheimer's treatment. #HealthTransformer #HealthMoonshot #AlzMoonshot Read ⤵️ https://bit.ly/4lNEFrU

Check out our most recent Peer Exchange discussion on NeurologyLive titled: Exploring New Advances in Parkinson Disease Management, where leading experts dive into the latest innovations, treatment strategies, and real-world clinical perspectives on Parkinson’s care! Watch the full discussion here: https://lnkd.in/eXk86jtc Stay tuned for future episodes in the series releasing over the next few weeks! #Parkinsons MJH Life Sciences®

In a recent NeurologyLive interview, Drs. Ditte Primdahl and Shailee Shah explore the complexities of paraneoplastic neurological syndromes (PNS)—rare, immune-mediated disorders that can precede a cancer diagnosis. They talk about how to spot signs of the condition, how certain cancer treatments can affect the immune system, and how new lab tools are helping doctors find and treat these rare disorders more accurately. Watch the full discussion here: https://lnkd.in/gactFxPh